Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04412616
Recruitment Status : Not yet recruiting
First Posted : June 2, 2020
Last Update Posted : June 2, 2020
Sponsor:
Collaborator:
Covance
Information provided by (Responsible Party):
Changchun Intellicrown Pharmaceutical Co. LTD

Brief Summary:
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced EGFR Positive Solid Tumor Biological: ZZ06 Phase 1

Detailed Description:
The study will start with an accelerated-titration dose escalation scheme, enrolling 1 patient per cohort for the first 2 cohorts with expansion to 3 patients in the event of Grade ≥ 2 treatment-emergent adverse event (TEAE) or dose limiting toxicity (DLT) possibly, probably, or definitely related to the study drug. After the first 2 cohorts, the study will then proceed to a 3+3 design, with enrollment of 3 patients per cohort and expansion to 6 patients in the event of a DLT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies
Estimated Study Start Date : June 1, 2020
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : October 6, 2022

Arm Intervention/treatment
Experimental: ZZ06 0.03 mg/kg dose group
ZZ06 0.03 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
Biological: ZZ06
The phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Experimental: ZZ06 0.06 mg/kg dose group
ZZ06 0.06 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
Biological: ZZ06
The phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Experimental: ZZ06 0.12 mg/kg dose group
ZZ06 0.12 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
Biological: ZZ06
The phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Experimental: ZZ06 0.22 mg/kg dose group
ZZ06 0.22 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
Biological: ZZ06
The phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Experimental: ZZ06 0.39 mg/kg dose group
ZZ06 0.39 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
Biological: ZZ06
The phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Experimental: ZZ06 0.70 mg/kg dose group
ZZ06 0.70 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
Biological: ZZ06
The phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Experimental: ZZ06 1.00 mg/kg dose group
ZZ06 1.00 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
Biological: ZZ06
The phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.




Primary Outcome Measures :
  1. ZZ06 AEs [ Time Frame: up to 36 weeks ]
    Adverse events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0

  2. Incidence of abnormal laboratory test results [ Time Frame: up to 36 weeks ]
    The data of the clinical laboratory evaluation is collected and analyzed according to the time point of the test flow chart

  3. Incidence of abnormal physical exam findings [ Time Frame: up to 36 weeks ]
    The data of the physical examinations is collected and analyzed according to the time point of the test flow chart


Secondary Outcome Measures :
  1. PK parameters: Area under curve (AUC) [ Time Frame: up to 28 weeks ]
    According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.

  2. PK parameters: Cmax [ Time Frame: up to 28 weeks ]
    According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.

  3. PK parameters: Clearance rate (CL) [ Time Frame: up to 28 weeks ]
    According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.

  4. PK parameters: t1/2 [ Time Frame: up to 28 weeks ]
    According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.

  5. PK parameters: Vz [ Time Frame: up to 28 weeks ]
    According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed advanced solid tumor that is positive for EGFR and has progressed despite standard therapy or for whom no standard therapy exists.
  • Patients are required to have archival tumor tissue available for assessment of EGFR status via FDA-approved EGFR assay .
  • Age ≥ 18 years.
  • Patients must have at least 1 measurable lesion as defined by RECIST v1.1.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.
  • Life expectancy ≥ 12 weeks.
  • Baseline organ function and laboratory data meet the following criteria:

    1. Bone marrow: ANC ≥ 1500 cells/mm3; Platelet count ≥ 75 000 cells/mm3; Hemoglobin ≥ 8.0 g/dL.
    2. Coagulation: Prothrombin time ≤ 1.5× ULN; Activated partial thromboplastin time ≤ 1.5× ULN;
    3. Renal function: Serum creatinine ≤ 1.5× ULN ; estimated glomerular filtration rate≥ 60 mL/min (Cockcroft-Gault formula).
    4. Hepatic function: Serum total bilirubin ≤ 1.5 mg/dL; AST and ALT ≤ 3.0× ULN (if metastases are present, ≤ 5.0× ULN).
  • Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.Patients must provide written informed consent prior to any study procedures.

Exclusion Criteria:

  • History of another primary cancer ≤ 3 years, with the exception of completely resected nonmelanoma skin cancer or carcinoma in situ of uterine cervix.
  • Active or symptomatic CNS metastases. Patients with treated CNS metastases that have been stable for ≥ 4 weeks and do not require treatment with steroids or anticonvulsants may be enrolled at the discretion of the Investigator.
  • Tests positive for hepatitis C virus, hepatitis B virus, or human immunodeficiency virus infection.
  • Active, clinically significant infections.
  • Clinically significant cardiovascular disease, including any of the following:

    1. Congestive heart failure (New York Heart Association Class > 2).
    2. Serious cardiac arrhythmia.
    3. Myocardial infarction ≤ 6 months.
    4. Unstable angina.
  • Prior clinically significant allergic reaction to chimerized or murine monoclonal antibody therapy.
  • Prior treatment ≤ 6 months with cetuximab, panitumomab, gefitinb, erlotinib, or other therapy that specifically and directly targets the EGF pathway.
  • Anticancer therapy or investigational agents for nonmalignant disease ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1, with the exception of tamoxifen for patients with a history of operated breast cancer > 3 years and no evidence of disease after surgery.
  • Major surgery ≤ 4 weeks.
  • Clinically significant psychiatric illness, other comorbidity, or laboratory abnormality that, in the opinion of the Investigator, makes it unsafe for the patient to participate in the study or may interfere with study compliance or study results.
  • Other unspecified reasons that, in the opinion of the Investigator, make the patient unsuitable for enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04412616


Contacts
Layout table for location contacts
Contact: Shiqi Bai 18943642700 baishiqi@intelli-crown.com

Sponsors and Collaborators
Changchun Intellicrown Pharmaceutical Co. LTD
Covance
Investigators
Layout table for investigator information
Principal Investigator: Sanjay Goel, MD Montefiore Medical Center
Layout table for additonal information
Responsible Party: Changchun Intellicrown Pharmaceutical Co. LTD
ClinicalTrials.gov Identifier: NCT04412616    
Other Study ID Numbers: 8379643
First Posted: June 2, 2020    Key Record Dates
Last Update Posted: June 2, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Changchun Intellicrown Pharmaceutical Co. LTD:
treatment-emergent adverse event (TEAE)
dose limiting toxicity (DLT)
pharmacokinetic (PK)
antidrug antibodies (ADA)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms